Given that both RNAi and GAS2DN inhibited the growth of leukemic cells, we started to perform experiments mainly with GAS2DN to study the efficacy and mechanism of the impaired CML cell growth induced by targeting GAS2. Here, GAS2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.